Close menu

June 12th, 2023 | 08:00 CEST

Disruption! From now on, everything will be different: PayPal, BYD, BioNXt

  • Biotechnology
  • Pharma
  • Electromobility
  • Software
Photo credits:

What is now called disruption in the startup scene has always existed. It refers to creative destruction, cutting old ties and rethinking things from the ground up. Companies that create marketable products in this way have an edge over the competition - and score points on the market with their uniqueness. We present three titles.

time to read: 3 minutes | Author: Nico Popp
ISIN: PAYPAL HDGS INC.DL-_0001 | US70450Y1038 , BYD CO. LTD H YC 1 | CNE100000296 , Bionxt Solutions Inc. | CA0909741062

Table of contents:

    Uwe Ahrens, Director, Altech Advanced Materials AG
    "[...] We know exactly what we are doing and are implementing what we consider to be a proven technology in an industrially applicable and scalable way. [...]" Uwe Ahrens, Director, Altech Advanced Materials AG

    Full interview


    PayPal's recipe for success: Easier, faster, cheaper

    When the payment service PayPal was founded in Palo Alto, California, in 1998, most people in Germany still dialled into the Internet via modem or ISDN. Marketplaces, such as online auction houses, only spread gradually and lived above all from their innovative power. Peter Thiel's team quickly realized that the comparatively young Internet would soon be of great commercial importance and that a payment service was needed. The following years can be summarized quickly: Since 2004, PayPal has been available in Germany, and since 2007, the Company has also had a banking licence in Europe.

    Compared to traditional financial institutions, PayPal quickly gained the upper hand on the internet - even though credit cards were initially the number one means of payment online. However, problems with security and handling drove customers to PayPal in droves. The cooperation with eBay, to which PayPal even belonged for a time, also contributed to the spread of the service. Those who regularly bought things at auction soon no longer wanted to use bank transfers and appreciated buyer protection. Today, PayPal is so strongly positioned in the market that one can trust the share despite recession worries. Despite the share price losses, PayPal is still up more than 65% over eight years.

    BYD: Flat screen instead of sports chassis

    The Chinese carmaker BYD is also something of a revolutionary. In the same period, the share even generated a return of a whopping 429% - and that despite the fact that the share is also already trading well below its all-time high. Why is that? BYD was an early adopter of electric mobility. This spring, it even stopped building internal combustion vehicles altogether. Another unique selling point of BYD is that the Company relies heavily on connectivity and technical bells and whistles. Large displays, WLAN, Bluetooth and lots of LEDs are more convincing to Chinese customers than a tight chassis. Why this is so is not surprising - after all, cars on China's roads send data to the authorities every thirty seconds. Driving pleasure is then quickly redefined. But back to BYD: As a promising company in the most important car market, the share is naturally highly rated. Whether the exit of Berkshire Hathaway or worries about a trade war between East and West: this market position is convincing and unique.

    BioNxt does it better and cheaper

    Completely free of worries about trade wars or financial crises are shareholders of the Canadian biotech BioNxt. The Company has positioned itself in various promising areas and sees itself as a problem solver within the healthcare system. The German subsidiary Vektor Pharma TF GmbH has developed a patch around the well-known Parkinson's drug rotigotine that can compete with original preparations in studies. A clinical trial of the product is currently underway, with the results expected by late summer. Only a few months ago, a court in the US cleared the way for generics in this very field. Also, a few months ago, BioNxt received an order to produce an orally soluble product. To fulfil this order, the Company has invested in a coating and cutting machine at its Biberach site.

    The business field of innovative dosage forms, which is also gaining commercial momentum, is extremely promising for BioNxt Solutions. The Company does not rule out acting as a contract manufacturer in other areas in the future. The dose can be adjusted depending on how effectively an active substance reaches the patient. This saves costs and strikes a chord with already cash-strapped healthcare systems worldwide. The incipient commercialization can be an opportunity for investors. In parallel, BioNxt is involved in the diagnostics sector, offering self-tests related to oral health. There is already a letter of intent for the production of biosensor products for testing inflammatory diseases of the oral cavity, such as those that occur as a side effect of drugs for opioid abuse, for the US market.

    Companies that have rethought tried-and-tested products from the ground up are also successful on the stock market - good examples are PayPal and BYD. BioNxt Solutions has made significant progress in the commercialization of its product range in recent months. If the positive trend continues and the figures are right, the share, which currently represents an enterprise value of around CAD 58 million, should be seen by many investors with new eyes.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 22nd, 2023 | 06:50 CEST

    Cardiol Therapeutics, BioNTech, BYD - At top speed to new markets

    • Biotechnology
    • Pharma
    • Electromobility

    Cardiol Therapeutics is enjoying a remarkable development. The biotech company is now rolling out its ARCHER patient recruitment trial internationally at 35 participating centers. This accelerates research in the development of their therapy to combat myocarditis, a heart inflammation which has been associated with COVID-19 vaccination. For Cardiol Therapeutics, this represents an opportunity to get its therapy approved as an orphan drug. Approval is also at stake for BioNTech. With a multimillion-dollar funding boost, the Company is working on accelerated approval for a vaccine against a virus that caused quite a stir last year. The shortened development time is likely to impress investors. While business nations agree on fighting viruses, they disagree on commodities for the road. The EU would prefer to restrict BYD's successful sales on domestic roads - by imposing tariffs. BYD, meanwhile, is tapping into a completely different market.


    Commented by Nico Popp on September 21st, 2023 | 07:00 CEST

    Turnaround cancelled? Where 100% is possible: Varta, BYD, Manuka Resources

    • Mining
    • Vanadium
    • PreciousMetals
    • Batteries
    • Electromobility

    When soccer players move to a better team, it usually comes with higher earnings. Sometimes, the training is more intense, and the tasks off the pitch are more extensive. It is no longer comparable to the idyllic life at their former club. Athletes are then faced with the question, "Give up or bite the bullet?" The situation is similar for battery pioneer Varta, which is implementing its e-car plans with Porsche, of all companies. The sports car manufacturer offers major growth opportunities but is also considered meticulous among engineers. We highlight Varta's stock, take a look at BYD and outline opportunities at a company many have never heard of!


    Commented by Nico Popp on September 20th, 2023 | 08:10 CEST

    Investing in Value Chains - The End for an Institution: AMS Osram, Volkswagen, Almonty

    • Mining
    • Tungsten
    • Electromobility
    • renewableenergies

    For years, the Transparent Factory in Dresden was a symbol of confidence at the end of the 1990s: Volkswagen wanted to catch up with the premium class in the modern car factory and had the Phaeton luxury sedan rolling off the production line there until 2016. After several years, during which the ID.3 electric car was manufactured there, the site is on the brink of closure - at least as a production facility. The property in the Elbe metropolis is too chic for VW not to find another use for it. The automotive industry is also undergoing change elsewhere. We outline three current cases and highlight possible investment opportunities.